cdmo.directory
← Compare landing

Asimov vs Minaris Advanced Therapies

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategoryAsimovMinaris Advanced Therapies
SummaryAsimov provides cell line development, upstream process development, and viral vector manufacturing services powered by proprietary synthetic biology platforms (CHO Edge, LV Edge, AAV Edge, RNA Edge) that deliver high-titer, stable cell lines and production systems for biologics, cell therapies, and gene therapies.Pure-play cell and gene therapy CDMO with over 25 years of GMP manufacturing, process development, and biosafety testing expertise. Serves advanced therapy innovators globally from early stage through commercialization.
Services
  • Biologics Development & Manufacturing
  • Monoclonal Antibody (mAb) Manufacturing
  • Recombinant Protein Manufacturing
  • Cell-Line Development
  • Upstream Processing
  • Viral Vector Manufacturing
  • AAV Manufacturing
  • Lentiviral Vector Manufacturing
  • Process Development
  • Technology Transfer
  • CMC Analytical Development
  • Monoclonal Antibody (mAb) Manufacturing
  • Recombinant Protein Manufacturing
  • Cell-Line Development
  • Viral Vector Manufacturing
  • AAV Manufacturing
  • Lentiviral Vector Manufacturing
  • Cell Therapy Manufacturing
  • Autologous Cell Therapy Manufacturing
  • Allogeneic Cell Therapy Manufacturing
  • Vaccine Manufacturing
  • Process Development
  • Technology Transfer
  • CMC Analytical Development
  • Quality Control Testing
  • Stability Testing & Storage
Modalities
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • AAV / Viral Vector Platform
Development capabilities
  • Analytical method development
  • Cell line development
  • Analytical method development
  • ICH stability testing
  • Cell line development
Manufacturing capabilities
  • Drug Substance (DS)
  • Max bioreactor: Mid-scale clinical (≤2,000 L)
  • Expression: Mammalian
  • Expression: Cell-Free
  • Single-Use / Disposable
  • Drug Substance (DS)
  • Drug Product (DP)
  • Expression: Mammalian
  • Expression: Viral Vector
Locations
  • Headquarters, Boston, MA, USA
  • Headquarters, Philadelphia, PA, United States
  • Philadelphia, Philadelphia, PA, United States
  • Allendale, Allendale, NJ, United States
  • Taufkirchen, Taufkirchen, Bavaria, Germany
  • London, London, England, United Kingdom
  • Yokohama, Yokohama, Kanagawa, Japan
  • Manufacturing & Testing, Philadelphia, PA, United States
  • Manufacturing, Allendale, NJ, United States
  • Manufacturing, Taufkirchen, Bavaria, Germany
  • Office, London, England, United Kingdom
  • Manufacturing, Yokohama, Kanagawa, Japan
  • Manufacturing & Testing, Allendale, NJ, United States
  • Manufacturing & Testing, Taufkirchen, Bavaria, Germany
  • Manufacturing & Testing, Yokohama, Kanagawa, Japan
CertificationsData not yet provided.
  • FDA · Identifier: Commercial manufacturing approval
  • EMA · Identifier: Commercial manufacturing approval
  • PMDA · Identifier: Commercial manufacturing approval
  • FDA · Identifier: FDA approval for commercial manufacturing
  • EMA · Identifier: EMA approval for commercial manufacturing
  • PMDA · Identifier: PMDA approval for commercial manufacturing

Find similar companies

Asimov alternatives · Minaris Advanced Therapies alternatives

Markdown mirror: /compare/asimov/wuxi-advanced-therapies.md